Antiplatelet therapy with a P2Y12 inhibitor is a key component of treatment for patients with acute coronary syndromes undergoing percutaneous coronary intervention.
In clinical trials that assessed the safety and efficacy of cangrelor during percutaneous coronary intervention (PCI), cangrelor was administered as a 30-μg/kg bolus followed by a 4-μg/kg/min infusion for at least 2 hours or the duration of the PCI, whichever was longer.
The Medicines Company announced the approval of Kengreal (cangrelor) by the FDA as an adjunctive therapy to percutaneous coronary intervention...
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
The Medicines Company has announced results for its pivotal Phase III clinical trial of cangrelor, which is in development to...
The Medicines Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
New data demonstrates that intravenous use of cangrelor, from AstraZeneca, was effective at maintaining platelet inhibition in patients on thienopyridines...
A pooled analysis of three Phase III clinical trials of cangrelor, from The Medicines Company, confirm the results of the...
Medicure announced that results from the investigator sponsored FABOLUS-FASTER Phase IV clinical trial, using Aggrastat (tirofiban) in acute coronary syndrome, have been published in Circulation, a peer-reviewed journal of the American Heart Association.